Skip to main content
Premium Trial:

Request an Annual Quote

Genteon, USC to Study Gene Expression, Mutation in Prostate Cancer

NEW YORK, July 18 - Privately held genomic-tool company Genteon and the Institute for Genetic Medicine at the University of Southern California today said they will partner to study prostate cancer.

 

The USC team, led by Juergen Reichardt of the Keck School of Medicine, will get access to Genteon's Capella 400 genetic-analysis system in order to study genomic mutations and gene expression in tumor samples.

 

The Capella system, which made its debut in October 2001, is Genteon's first I-tool. It is an automated 384-capillary electrophoresis system equipped with dynamic fluorescent detection.

 

Click here for more information.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.